Observation of the efficacy of metoprolol succinate sustained-release tablets combined with trimetazidine in the treatment of heart failure patients with preserved left ventricular ejection fraction

Objective To observe the efficacy of metoprolol succinate sustained-release tablets combined with trimetazidine in the treatment of heart failure patients with preserved left ventricular ejection fraction (HF-PEF). MethodsA total of 90 patients with HF-PEF were randomly divided into a conventional treatment group and a combined treatment group (n=45). Patients in the conventional treatment group were administrated with metoprolol succinate sustained-release tablets to treat heart failure, while those in the combined treatment group were given trimetazidine in addition to metoprolol succinate sustained-release tablets. After follow-up visits for six months, the two groups were compared for the New York Heart Association (NYHA) cardiac function, the level of B-type natriuretic peptide (BNP), the diastolic function of left ventricle and the distance of six minutes walking test before and after treatment. ResultsCompared with the conventional treatment group, the combined treatment group presented enhanced NYHA cardiac function (P<0.05), and showed increases in E/A ratio (P<0.05) and the distance of six minutes walking test (P<0.01) but decreases in E/e′ ratio and BNP level (each P<0.01). ConclusionsThe combined use of metoprolol succinate sustained-release tablets and trimentazidine can improve the cardiac function, left ventricular diastolic function and quality of life in patients with HF-PEF.